Recent News

• 01.07.2026 - Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
• 12.19.2025 - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
• 12.18.2025 - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
• 11.19.2025 - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Recent Filings

• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 8-K Current report
• 01.02.2026 - 8-K Current report
• 12.29.2025 - PRE 14A Other preliminary proxy statements
• 12.19.2025 - 8-K Current report
• 12.19.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.19.2025 - EX-99.1 EX-99.1
• 11.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.24.2025 - 3 Initial statement of beneficial ownership of securities
• 11.24.2025 - 3 Initial statement of beneficial ownership of securities